TAXOTERE
Produced by Sanofi-Aventis, Taxotere is a chemotherapy drug. In fact, it is one of the most often prescribed chemotherapy drugs in its class, earning Sanofi more than $3 billion in just one year. Many doctors use Taxotere in the treatment of their breast-cancer patients.
Unfortunately, this drug has been linked to side effects that permanently impact the lives of many women.
To date, approximately nine percent of breast cancer patients have sustained prolonged or permanent hair loss, also known as alopecia. This irreversible effect has a considerable impact on many women who report experiencing depression, distress, and anxiety after losing their hair.
It is alleged that Sanofi should be held responsible for a variety of actions such as these:
- Selling the drug before adequately testing it
- Hiding information from the public about the drug’s side effects
- Selling the drug before thoroughly informing patients about risks and dangers
- Using misleading advertising
- Failing to warn doctors about the drug’s associated risks
- Downplaying the risks of the drug
Many patients claim that they would have opted for a comparable chemotherapy drug with less of a risk for hair loss had they been fully aware of the risks surrounding Taxotere.